Respiri - Wheezo to begin patient use in the US
Respiri has announced that, along with partner Access Telehealth, it has successfully concluded a system integration of the companies’ platforms with the Michigan Children’s Hospital, the company’s first US customer. This includes Respiri’s proprietary wheezo device, application and health portal (which manages respiratory health data) along with Access Telehealth’s remote patient monitoring (RPM) platform, Remotli. Patient intake is expected to start in the coming weeks and would mark the first patient use of wheezo in the US, feedback from which is likely to set the direction for future uptake. We highlight that the market for wheezo in the US is expected to be physician led and, unlike Respiri’s domestic Australian market, is reimbursed under the relevant RPM procedural terminology codes. The US market therefore presents a significant opportunity for Respiri.Respiri is engaged in the research, development and commercialization of medical devices, and the development of mobile health applications. Co.'s reportable segments are Australia and Israel.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.